Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 339

1.

T Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.

Lapteva N, Gilbert M, Diaconu I, Rollins LA, Al-Sabbagh M, Naik S, Krance R, Tripic T, Hiregange M, Raghavan D, Dakhova O, Rouce RH, Liu H, Omer B, Savoldo B, Dotti G, Cruz CR, Sharpe K, Gates M, Orozco A, Durett A, Pacheco E, Gee AP, Ramos CA, Heslop HE, Brenner MK, Rooney CM.

Clin Cancer Res. 2019 Sep 26. pii: clincanres.3199.2018. doi: 10.1158/1078-0432.CCR-18-3199. [Epub ahead of print]

PMID:
31558475
2.

Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients.

Naik S, Martinez CA, Omer B, Sasa G, Yassine K, Allen CE, Kamdar K, Orth R, Wu M, Leung K, Gottschalk S, Brenner MK, Heslop HE, Krance RA.

Blood Adv. 2019 Sep 24;3(18):2689-2695. doi: 10.1182/bloodadvances.2018026203.

3.

"Mini" bank of only 8 donors supplies CMV-directed T cells to diverse recipients.

Tzannou I, Watanabe A, Naik S, Daum R, Kuvalekar M, Leung KS, Martinez C, Sasa G, Wu M, Gee AP, Krance RA, Gottschalk S, Heslop HE, Omer B.

Blood Adv. 2019 Sep 10;3(17):2571-2580. doi: 10.1182/bloodadvances.2019000371.

4.

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.

Jain T, Bar M, Kansagra AJ, Chong EA, Hashmi SK, Neelapu SS, Byrne M, Jacoby E, Lazaryan A, Jacobson CA, Ansell SM, Awan FT, Burns L, Bachanova V, Bollard CM, Carpenter PA, DiPersio JF, Hamadani M, Heslop HE, Hill JA, Komanduri KV, Kovitz CA, Lazarus HM, Serrette JM, Mohty M, Miklos D, Nagler A, Pavletic SZ, Savani BN, Schuster SJ, Kharfan-Dabaja MA, Perales MA, Lin Y.

Biol Blood Marrow Transplant. 2019 Aug 22. pii: S1083-8791(19)30529-4. doi: 10.1016/j.bbmt.2019.08.015. [Epub ahead of print] Review.

PMID:
31446199
5.

Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.

Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT.

Transpl Infect Dis. 2019 Jul 12:e13145. doi: 10.1111/tid.13145. [Epub ahead of print]

PMID:
31301099
6.

T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.

Keller MD, Darko S, Lang H, Ransier A, Lazarski CA, Wang Y, Hanley PJ, Davila BJ, Heimall JR, Ambinder RF, Barrett AJ, Rooney CM, Heslop HE, Douek DC, Bollard CM.

Br J Haematol. 2019 Oct;187(2):206-218. doi: 10.1111/bjh.16053. Epub 2019 Jun 20.

PMID:
31219185
7.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Bone Marrow Transplant. 2019 May 15. doi: 10.1038/s41409-019-0451-2. [Epub ahead of print]

PMID:
31092900
8.

Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells.

Steffin DHM, Heslop HE.

Mol Ther. 2019 May 8;27(5):900-901. doi: 10.1016/j.ymthe.2019.04.007. Epub 2019 Apr 18. No abstract available.

PMID:
31005599
9.

Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR.

Leung W, Heslop HE.

Cancer Immunol Res. 2019 Apr;7(4):528-533. doi: 10.1158/2326-6066.CIR-18-0888. Review.

PMID:
30936089
10.

Harmonizing Immune Effector Toxicity Reporting.

Heslop HE, Shpall EJ.

Biol Blood Marrow Transplant. 2019 Apr;25(4):e121-e122. doi: 10.1016/j.bbmt.2019.01.001. Epub 2019 Jan 5.

PMID:
30615980
11.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e76-e85. doi: 10.1016/j.bbmt.2018.12.068. Epub 2018 Dec 18.

PMID:
30576834
12.

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.

Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti G.

Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13.

PMID:
30309819
13.

EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.

McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CM.

Blood. 2018 Nov 29;132(22):2351-2361. doi: 10.1182/blood-2018-07-863654. Epub 2018 Sep 27.

PMID:
30262660
14.

Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium.

Nishiyama-Fujita Y, Kawana-Tachikawa AI, Ono T, Tanaka Y, Kato T, Heslop HE, Morio T, Takahashi S.

Cytotherapy. 2018 Sep;20(9):1182-1190. doi: 10.1016/j.jcyt.2018.05.009. Epub 2018 Aug 17.

PMID:
30122653
15.

A backpack revs up T-cell activity.

Shum T, Heslop HE.

Nat Biotechnol. 2018 Aug 6;36(8):702-703. doi: 10.1038/nbt.4215. No abstract available.

PMID:
30080841
16.

The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma.

Lulla PD, Hill LC, Ramos CA, Heslop HE.

Clin Adv Hematol Oncol. 2018 May;16(5):375-386. Review.

17.

Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis.

Chinn IK, Eckstein OS, Peckham-Gregory EC, Goldberg BR, Forbes LR, Nicholas SK, Mace EM, Vogel TP, Abhyankar HA, Diaz MI, Heslop HE, Krance RA, Martinez CA, Nguyen TC, Bashir DA, Goldman JR, Stray-Pedersen A, Pedroza LA, Poli MC, Aldave-Becerra JC, McGhee SA, Al-Herz W, Chamdin A, Coban-Akdemir ZH, Jhangiani SN, Muzny DM, Cao TN, Hong DN, Gibbs RA, Lupski JR, Orange JS, McClain KL, Allen CE.

Blood. 2018 Jul 5;132(1):89-100. doi: 10.1182/blood-2017-11-814244. Epub 2018 Apr 9.

18.

High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease.

Yanir AD, Hanson IC, Shearer WT, Noroski LM, Forbes LR, Seeborg FO, Nicholas S, Chinn I, Orange JS, Rider NL, Leung KS, Naik S, Carrum G, Sasa G, Hegde M, Omer BA, Ahmed N, Allen CE, Khaled Y, Wu MF, Liu H, Gottschalk SM, Heslop HE, Brenner MK, Krance RA, Martinez CA.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1643-1650. doi: 10.1016/j.bbmt.2018.03.029. Epub 2018 Apr 6.

19.

Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016.

Yanir AD, Martinez CA, Sasa G, Leung K, Gottschalk S, Omer B, Ahmed N, Hegde M, Eunji J, Liu H, Heslop HE, Brenner MK, Krance RA, Naik S.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1424-1431. doi: 10.1016/j.bbmt.2018.03.001. Epub 2018 Mar 14.

20.

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.

Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM.

J Clin Oncol. 2018 Apr 10;36(11):1128-1139. doi: 10.1200/JCO.2017.74.3179. Epub 2018 Jan 9.

21.

Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy.

Heslop HE, Brenner MK.

Mol Ther. 2018 Jan 3;26(1):1-2. doi: 10.1016/j.ymthe.2017.12.004. Epub 2017 Dec 20. No abstract available.

22.

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.

Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B.

J Clin Invest. 2017 Sep 1;127(9):3462-3471. doi: 10.1172/JCI94306. Epub 2017 Aug 14.

23.

Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.

Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B.

J Clin Oncol. 2017 Nov 1;35(31):3547-3557. doi: 10.1200/JCO.2017.73.0655. Epub 2017 Aug 7.

24.

Equal opportunity CAR T cells.

Rouce RH, Heslop HE.

Blood. 2017 Jun 22;129(25):3275-3277. doi: 10.1182/blood-2017-04-779983. No abstract available.

25.

CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.

Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK.

Mol Ther. 2017 Sep 6;25(9):2214-2224. doi: 10.1016/j.ymthe.2017.05.012. Epub 2017 Jun 9.

26.

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S.

JAMA Oncol. 2017 Aug 1;3(8):1094-1101. doi: 10.1001/jamaoncol.2017.0184.

27.

Fine-tuning the CAR spacer improves T-cell potency.

Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF.

Oncoimmunology. 2016 Nov 8;5(12):e1253656. doi: 10.1080/2162402X.2016.1253656. eCollection 2016.

28.

Exhausting alloreactivity of donor-derived CAR T cells.

Mamonkin M, Heslop HE.

Nat Med. 2017 Feb 7;23(2):147-148. doi: 10.1038/nm.4276. No abstract available.

PMID:
28170385
29.

Fall of the mutants: T cells targeting BCR-ABL.

Lulla P, Heslop HE.

Blood. 2017 Feb 2;129(5):539-540. doi: 10.1182/blood-2016-12-757336. No abstract available.

30.

Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.

Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM, Vera JF.

Mol Ther. 2017 Jan 4;25(1):249-258. doi: 10.1016/j.ymthe.2016.10.016. Epub 2017 Jan 4.

31.

Checkpoint inhibition and cellular immunotherapy in lymphoma.

Lulla P, Heslop HE.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):390-396. Review.

32.

Recent advances in T-cell immunotherapy for haematological malignancies.

Rouce RH, Sharma S, Huynh M, Heslop HE.

Br J Haematol. 2017 Mar;176(5):688-704. doi: 10.1111/bjh.14470. Epub 2016 Nov 29. Review.

33.

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains.

Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G.

J Clin Invest. 2016 Jul 1;126(7):2588-96. doi: 10.1172/JCI86000. Epub 2016 Jun 6.

34.

Forecasting Cytokine Storms with New Predictive Biomarkers.

Rouce RH, Heslop HE.

Cancer Discov. 2016 Jun;6(6):579-80. doi: 10.1158/2159-8290.CD-16-0493.

35.

T cells for viral infections after allogeneic hematopoietic stem cell transplant.

Bollard CM, Heslop HE.

Blood. 2016 Jun 30;127(26):3331-40. doi: 10.1182/blood-2016-01-628982. Epub 2016 May 20. Review.

36.

Policy: Global standards for stem-cell research.

Kimmelman J, Hyun I, Benvenisty N, Caulfield T, Heslop HE, Murry CE, Sipp D, Studer L, Sugarman J, Daley GQ.

Nature. 2016 May 19;533(7603):311-3. doi: 10.1038/533311a. No abstract available.

PMID:
27193661
37.

Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines.

Daley GQ, Hyun I, Apperley JF, Barker RA, Benvenisty N, Bredenoord AL, Breuer CK, Caulfield T, Cedars MI, Frey-Vasconcells J, Heslop HE, Jin Y, Lee RT, McCabe C, Munsie M, Murry CE, Piantadosi S, Rao M, Rooke HM, Sipp D, Studer L, Sugarman J, Takahashi M, Zimmerman M, Kimmelman J.

Stem Cell Reports. 2016 Jun 14;6(6):787-797. doi: 10.1016/j.stemcr.2016.05.001. Epub 2016 May 12.

38.

New ISSCR guidelines: clinical translation of stem cell research.

Kimmelman J, Heslop HE, Sugarman J, Studer L, Benvenisty N, Caulfield T, Hyun I, Murry CE, Sipp D, Daley GQ.

Lancet. 2016 May 14;387(10032):1979-81. No abstract available.

PMID:
27179752
39.

Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.

Naik S, Nicholas SK, Martinez CA, Leen AM, Hanley PJ, Gottschalk SM, Rooney CM, Hanson IC, Krance RA, Shpall EJ, Cruz CR, Amrolia P, Lucchini G, Bunin N, Heimall J, Klein OR, Gennery AR, Slatter MA, Vickers MA, Orange JS, Heslop HE, Bollard CM, Keller MD.

J Allergy Clin Immunol. 2016 May;137(5):1498-1505.e1. doi: 10.1016/j.jaci.2015.12.1311. Epub 2016 Feb 24.

40.

Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation.

Zhou X, Naik S, Dakhova O, Dotti G, Heslop HE, Brenner MK.

Mol Ther. 2016 Apr;24(4):823-31. doi: 10.1038/mt.2015.234. Epub 2015 Dec 28.

41.

Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch.

Chang EC, Liu H, West JA, Zhou X, Dakhova O, Wheeler DA, Heslop HE, Brenner MK, Dotti G.

Mol Ther. 2016 Apr;24(4):736-45. doi: 10.1038/mt.2015.217. Epub 2015 Dec 7.

42.

CAR-T Cell Therapy for Lymphoma.

Ramos CA, Heslop HE, Brenner MK.

Annu Rev Med. 2016;67:165-83. doi: 10.1146/annurev-med-051914-021702. Epub 2015 Aug 26. Review.

43.

Antigen-specific T cell therapies for cancer.

Manzo T, Heslop HE, Rooney CM.

Hum Mol Genet. 2015 Oct 15;24(R1):R67-73. doi: 10.1093/hmg/ddv270. Epub 2015 Jul 9. Review.

44.

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.

Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MK.

Blood. 2015 Jun 25;125(26):4103-13. doi: 10.1182/blood-2015-02-628354. Epub 2015 May 14.

45.

Engineering haploidentical transplants.

Naik S, Heslop HE.

Bone Marrow Transplant. 2015 Jul;50(7):884-5. doi: 10.1038/bmt.2015.115. Epub 2015 May 11. No abstract available.

PMID:
25961777
46.

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA.

Blood. 2015 Jun 18;125(25):3905-16. doi: 10.1182/blood-2015-01-621474. Epub 2015 May 4.

47.

CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.

Hanley PJ, Melenhorst JJ, Nikiforow S, Scheinberg P, Blaney JW, Demmler-Harrison G, Cruz CR, Lam S, Krance RA, Leung KS, Martinez CA, Liu H, Douek DC, Heslop HE, Rooney CM, Shpall EJ, Barrett AJ, Rodgers JR, Bollard CM.

Sci Transl Med. 2015 Apr 29;7(285):285ra63. doi: 10.1126/scitranslmed.aaa2546. Erratum in: Sci Transl Med. 2016 Jan 13;8(321):321er1.

48.

Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.

Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S.

J Clin Oncol. 2015 May 20;33(15):1688-96. doi: 10.1200/JCO.2014.58.0225. Epub 2015 Mar 23.

49.

Survivin-specific T cell receptor targets tumor but not T cells.

Arber C, Feng X, Abhyankar H, Romero E, Wu MF, Heslop HE, Barth P, Dotti G, Savoldo B.

J Clin Invest. 2015 Jan;125(1):157-68. doi: 10.1172/JCI75876. Epub 2014 Nov 21.

50.

Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.

Melenhorst JJ, Castillo P, Hanley PJ, Keller MD, Krance RA, Margolin J, Leen AM, Heslop HE, Barrett AJ, Rooney CM, Bollard CM.

Mol Ther. 2015 Jan;23(1):179-83. doi: 10.1038/mt.2014.192. Epub 2014 Sep 30.

Supplemental Content

Loading ...
Support Center